US10300253B2 - Weeping balloon with flow channels for reduced infusion pressure - Google Patents
Weeping balloon with flow channels for reduced infusion pressure Download PDFInfo
- Publication number
- US10300253B2 US10300253B2 US15/336,017 US201615336017A US10300253B2 US 10300253 B2 US10300253 B2 US 10300253B2 US 201615336017 A US201615336017 A US 201615336017A US 10300253 B2 US10300253 B2 US 10300253B2
- Authority
- US
- United States
- Prior art keywords
- balloon
- end portion
- inner balloon
- distal end
- proximal end
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 238000001802 infusion Methods 0.000 title description 8
- 238000000034 method Methods 0.000 claims abstract description 30
- 238000005520 cutting process Methods 0.000 claims abstract description 4
- 239000012530 fluid Substances 0.000 claims description 81
- 238000004891 communication Methods 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 6
- 238000003698 laser cutting Methods 0.000 claims description 5
- 238000000227 grinding Methods 0.000 claims description 3
- 239000000463 material Substances 0.000 description 19
- 239000003814 drug Substances 0.000 description 16
- 229940124597 therapeutic agent Drugs 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000002659 cell therapy Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 229920002614 Polyether block amide Polymers 0.000 description 4
- 230000000692 anti-sense effect Effects 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- VPRUMANMDWQMNF-UHFFFAOYSA-N phenylethane boronic acid Chemical compound OB(O)CCC1=CC=CC=C1 VPRUMANMDWQMNF-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 241000217377 Amblema plicata Species 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- JHWNWJKBPDFINM-UHFFFAOYSA-N Laurolactam Chemical compound O=C1CCCCCCCCCCCN1 JHWNWJKBPDFINM-UHFFFAOYSA-N 0.000 description 2
- 229920000299 Nylon 12 Polymers 0.000 description 2
- 239000004721 Polyphenylene oxide Substances 0.000 description 2
- 229920003232 aliphatic polyester Polymers 0.000 description 2
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- -1 poly(ethylene terephthalate) Polymers 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000570 polyether Polymers 0.000 description 2
- 229920000139 polyethylene terephthalate Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- MHCMWGPPLOSCJY-UHFFFAOYSA-N 4-$l^{1}-azanylmorpholine Chemical compound [N]N1CCOCC1 MHCMWGPPLOSCJY-UHFFFAOYSA-N 0.000 description 1
- 229910000014 Bismuth subcarbonate Inorganic materials 0.000 description 1
- 108091028690 C-myc mRNA Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 229920001634 Copolyester Polymers 0.000 description 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000013 bile duct Anatomy 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 238000012925 biological evaluation Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052797 bismuth Inorganic materials 0.000 description 1
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
- MGLUJXPJRXTKJM-UHFFFAOYSA-L bismuth subcarbonate Chemical compound O=[Bi]OC(=O)O[Bi]=O MGLUJXPJRXTKJM-UHFFFAOYSA-L 0.000 description 1
- 229940036358 bismuth subcarbonate Drugs 0.000 description 1
- WMWLMWRWZQELOS-UHFFFAOYSA-N bismuth(III) oxide Inorganic materials O=[Bi]O[Bi]=O WMWLMWRWZQELOS-UHFFFAOYSA-N 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 229920006147 copolyamide elastomer Polymers 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013013 elastic material Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 229920000554 ionomer Polymers 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1027—Making of balloon catheters
- A61M25/1029—Production methods of the balloon members, e.g. blow-moulding, extruding, deposition or by wrapping a plurality of layers of balloon material around a mandril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1002—Balloon catheters characterised by balloon shape
- A61M2025/1004—Balloons with folds, e.g. folded or multifolded
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M25/1011—Multiple balloon catheters
- A61M2025/1013—Multiple balloon catheters with concentrically mounted balloons, e.g. being independently inflatable
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/10—Balloon catheters
- A61M2025/1043—Balloon catheters with special features or adapted for special applications
- A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
Definitions
- the present application relates to medical catheters configured to release a therapeutic agent. More particularly, the present application relates to medical multiple balloon catheters that include having an inner balloon and an outer balloon and one or more flow channels therebetween.
- the inner balloon is inflated to approximately 2 ATM and a significant part of the infusion pressure is used to create a flow path between the pressurized inner balloon and the perforated outer balloon. If the infusion pressure is too high, then the physical stress on the cells in cell therapy and other forms of medical treatment is too high. Moreover, the high cost to manufacture medical multiple balloon catheters that effectively deliver cell therapy with a low infusion pressure is also a concern for many consumers.
- the present invention seeks to provide an improved method of forming a multiple-balloon intraluminal fluid delivery catheter for delivering a fluid into a body vessel.
- the method includes extruding a tube and a plurality of ribs through a die to form a monolithic single element that has a length that spans between a first end and a second end with the plurality of ribs extending along the length of the tube, the plurality of ribs defining a corresponding number of a plurality of channels that extend along the length of the tube.
- the method further includes positioning a portion of the tube into a mold, the mold having a corresponding number of grooves sized and positioned to receive the plurality of ribs on the tube and constricting a proximal end portion near the first end and a distal end portion near the second end of the portion of the tube that is positioned in the mold. Thereafter the method includes inflating the tube to produce an inner balloon, the inner balloon having a body portion that spans between the proximal end portion and the distal end portion and cutting the inner balloon near the proximal end portion and near the distal end portion to separate the inner balloon from a remainder of the tube. Lastly the method includes disposing an outer balloon around the inner balloon, the outer balloon being movable between a compressed configuration and an expanded configuration, the outer balloon including a plurality of holes.
- the method includes aligning the plurality of holes of the outer balloon with the plurality of channels on the inner balloon.
- the method includes heating the portion of the tube in the mold and stretching the portion of the tube in the mold.
- the constricting includes radially compressing the proximal end portion and the distal end portion.
- the method includes mounting the inner balloon on a catheter shaft and mounting the outer balloon around at least a portion of the inner balloon. The method may reduce the height of the plurality of ribs by a linear amount along the proximal end portion and the distal end portion to reduce the stiffness of the plurality of ribs.
- the method may reduce the height of the plurality of ribs by laser cutting or grinding a portion of each of the plurality of ribs.
- the method may reduce the height of the plurality of ribs while inflating the tube to produce the inner balloon.
- the method may cut the inner balloon before the reducing the height of the plurality of ribs.
- the catheter includes an outer balloon mounted around the inner balloon, the outer balloon having a middle portion that spans between a proximal end and a distal end, the outer balloon being movable between a compressed configuration and an expanded configuration, the outer balloon including a plurality of holes.
- the inner balloon and the outer balloon are configured and oriented such that a plurality of flow channels are defined when the inner balloon is in the inflated configuration and the outer balloon is in the expanded configuration and a portion of each of the plurality of ridges that spans along the middle portion engage an inner surface of the outer balloon, the inflated configuration of the inner balloon and the expanded configuration of the outer balloon defines an annular lumen there between, the annular lumen and the plurality of flow channels being in communication with the fluid delivery lumen and the plurality of holes such that the annular lumen and the plurality of flow channels are configured to promote delivery of said fluid through the plurality of holes, the annular lumen having a constant cross-sectional area along the longitudinal axis.
- the plurality of ridges along the middle portion of the inner balloon engages the inner surface of the outer balloon.
- the multiple balloon intraluminal fluid delivery catheter may include the plurality of ridges along the middle portion, the proximal end portion, and the distal end portion of the inner balloon engage the inner surface of the outer balloon.
- the multiple balloon intraluminal fluid delivery catheter may include the plurality of holes that are uniformly spaced along the longitudinal axis.
- the multiple balloon intraluminal fluid delivery catheter may also have the plurality of flow channels that have a constant cross-sectional area along the longitudinal axis.
- FIG. 1 is a front view of one embodiment of a multiple balloon catheter.
- FIG. 2A is a transverse cross-sectional view along line 2 A- 2 A of the multiple balloon catheter shown in FIG. 1 .
- FIG. 2B is a transverse cross-sectional view along line 2 B- 2 B of the multiple balloon catheter shown in FIG. 1 .
- FIG. 2C is a transverse cross-sectional view along line 2 C- 2 C of the multiple balloon catheter shown in FIG. 1 .
- FIG. 3 is a partial longitudinal cross-sectional view of the multiple balloon catheter shown in FIG. 1 .
- FIG. 4 is a partial longitudinal cross-sectional view of an inner balloon before the inner balloon is assembled with the outer balloon shown in FIG. 3 .
- FIG. 5 is a partial longitudinal cross-sectional view of a second embodiment of an inner balloon.
- FIG. 6 is a partial longitudinal cross-sectional view of a third embodiment of an inner balloon.
- FIG. 7 is a perspective end view of an embodiment of raw material tubing used to produce the inner balloons of FIGS. 1, 2A-2C, 3, 4, 5, and 6 .
- FIG. 8 is an end view of the raw material tubing of FIG. 7 .
- FIG. 9 is a transverse cross-sectional view of a multiple balloon catheter.
- the term “implantable” refers to an ability of a medical device to be positioned at a location within a body, such as within a body vessel. Furthermore, the terms “implantation” and “implanted” refer to the positioning of a medical device at a location within a body, such as within a body vessel.
- biocompatible refers to a material that is substantially non-toxic in the in vivo environment of its intended use and that is not substantially rejected by the patient's physiological system (i.e., is non-antigenic). This can be gauged by the ability of a material to pass the biocompatibility tests set forth in International Standards Organization (ISO) Standard No. 10993 and/or the U.S. Pharmacopeia (USP) 23 and/or the U.S. Food and Drug Administration (FDA) blue book memorandum No.
- ISO International Standards Organization
- USP U.S. Pharmacopeia
- FDA U.S. Food and Drug Administration
- G95-1 entitled “Use of International Standard ISO-10993, Biological Evaluation of Medical Devices Part-1: Evaluation and Testing.” Typically, these tests measure a material's toxicity, infectivity, pyrogenicity, irritation potential, reactivity, hemolytic activity, carcinogenicity, and/or immunogenicity.
- a biocompatible structure or material when introduced into a majority of patients, will not cause an undesirably adverse, long-lived or escalating biological reaction or response and is distinguished from a mild, transient inflammation which typically accompanies surgery or implantation of foreign objects into a living organism.
- body vessel means any body passage lumen that conducts fluid, including but not limited to blood vessels, esophageal, intestinal, biliary, urethral, and ureteral passages.
- the medical devices of the embodiments described herein can be oriented in any suitable absolute orientation with respect to a body vessel.
- the recitation of a “first” direction is provided as an example. Any suitable orientation or direction can correspond to a “first” direction.
- the first direction can be a radial direction in some embodiments.
- FIGS. 1, 2A, 2B, 2C, and 3 illustrate an example embodiment of a medical device comprising a multiple balloon catheter 10 or weeping balloon catheter made with the present disclosure.
- the multiple balloon catheter 10 extends from a proximal end 12 to a distal end 14 .
- the multiple balloon catheter 10 includes a manifold 16 located near a proximal end region 18 of the multiple balloon catheter 10 and a multiple balloon assembly 20 at a distal end region 19 of the multiple balloon catheter 10 .
- the manifold 16 is operatively connected to a catheter shaft 22 in the proximal end region 18 .
- the catheter shaft 22 extends from a proximal end 26 to a distal end 28 .
- the manifold 16 can include an injection port 32 and an inflation port 34 .
- the catheter shaft 22 can include an inflation lumen 30 , a fluid delivery lumen 33 ( FIG. 3 ) spaced from the inflation lumen 30 , and a wire guide lumen 38 .
- the catheter shaft 22 can also include one or more conventional fittings and/or adapters between the manifold 16 and the proximal end 26 of the catheter shaft 22 .
- the multiple balloon catheter 10 can be a “short wire” system having a wire guide port 23 within an intermediate region of the catheter shaft 22 , providing access to the wire guide lumen 38 extending through the catheter shaft 22 from the wire guide port 23 to the distal end 14 of the multiple balloon catheter 10 , as shown in FIG. 1 .
- the multiple balloon catheter 10 can be an “over the wire” system with the wire guide port 23 positioned as part of the manifold 16 .
- the manifold 16 includes the wire guide port 23 in addition to the inflation port 34 and the injection port 32 .
- the multiple balloon catheter assembly 20 includes a perforated outer balloon 42 radially disposed around an inner balloon 40 .
- the inner balloon 40 is non-porous and in fluid communication with the inflation port 34 through the body of the catheter shaft 22 .
- the outer balloon 42 includes a plurality of holes 46 and is in fluid communication with the injection port 32 through the catheter shaft 22 and separated from both the inner balloon 40 and the inflation port 34 .
- the individual holes within the plurality of holes 46 are uniformly positioned along the outer balloon 42 .
- the individual holes within the plurality of holes 46 can have an alternative distribution such as variable spacing, grouped spacing, or evenly spaced.
- the inner balloon 40 has a generally uniform cross-sectional area moving distally along a longitudinal axis 24
- the outer balloon 42 has a corresponding cross-sectional area that is similar to the inner balloon 40 .
- the profile and cross-sectional area of both the inner balloon 40 and the outer balloon 42 is described in more detail below.
- an annular balloon fluid delivery lumen 44 for receiving a therapeutic agent or fluid, such as a diagnostic media, from the injection port 32 via the fluid delivery lumen 33 can be formed between the inner balloon 40 and the outer balloon 42 .
- Both the inner balloon 40 and the outer balloon 42 can be sealed to the distal end 28 of the catheter shaft 22 .
- the multiple balloon assembly 20 can be translated over a wire guide 36 that is shown extending from the wire guide port 23 , through the catheter shaft 22 and extending through the distal end 14 of the multiple balloon catheter 10 .
- the multiple balloon assembly 20 is typically provided separately from the wire guide 36 , an introducer sheath (not shown) or other devices typically used to insert the multiple balloon assembly 20 within a body vessel.
- the catheter shaft 22 of the multiple balloon catheter 10 is shaped and configured for the intended use in a body vessel.
- the catheter shaft 22 includes the wire guide lumen 38 configured to house a wire guide 36 .
- the wire guide lumen 38 has an inside diameter of about approximately 0.5 mm but can be smaller from about 0.25 mm or larger to about 1.0 mm.
- the overall length of the catheter shaft 22 can be approximately 110 cm to about 180 cm or smaller from about 50 cm to about 80 cm.
- the outside diameter of the catheter shaft 22 is typically approximately 1-1.5 mm, but can be up to about 3.5 mm. Further details regarding the manufacturing and/or assembling of the catheter shaft 22 are described in U.S. PCT Application Number US2008/75970 filed on Sep. 11, 2008, published as WO 2009/036135 A1, which is incorporated by reference.
- FIG. 2A is a transverse cross-sectional view of the multiple balloon assembly 20 along line 2 A- 2 A in FIG. 1 showing a proximal end of the multiple balloon assembly 20 of the multiple balloon catheter 10 .
- the inner balloon 40 includes a tubular member 41 defining the inflation lumen 30 and a tubular member 43 defining the wire guide lumen 38 .
- the inflation lumen 30 and the fluid delivery lumen 33 (not shown in FIG. 2A ) are in isolation from one another.
- the fluid delivery lumen 33 is in fluid communication with the annular balloon fluid delivery lumen 44 , which is shown between the outer balloon 42 and the inner balloon 40 .
- FIG. 2B is a transverse cross-sectional view of the multiple balloon assembly 20 along line 2 B- 2 B in FIG. 1 that is distally located from the line 2 A- 2 A, showing a proximal portion of the multiple balloon assembly 20 of the multiple balloon catheter 10 in the inflated configuration.
- the inner balloon 40 shown as tapered and described below in more detail, defines the inflation lumen 30 extending radially around the tubular member 43 that defines the wire guide lumen 38 .
- the annular balloon fluid delivery lumen 44 is shown to be in between the outer balloon 42 and the inner balloon 40 .
- the cross-sectional area or diameter of the annular balloon fluid delivery lumen 44 is generally constant along the length of the inner balloon 40 .
- FIG. 2C is a transverse cross-sectional view of the multiple balloon assembly 20 along line 2 C- 2 C in FIG. 1 that is distally located from the line 2 B- 2 B, showing a body portion 50 and a middle portion 70 of the multiple balloon assembly 20 of the multiple balloon catheter 10 in the inflated configuration.
- the inner balloon 40 defines the inflation lumen 30 extending radially around the tubular member 43 that defines the wire guide lumen 38 .
- the holes 46 are in fluid communication with the annular balloon fluid delivery lumen 44 , which is shown between the outer balloon 42 and the inner balloon 40 .
- the inner balloon 40 having a proximal end 47 and a distal end 49 is mounted at the distal end 14 of the catheter shaft 22 .
- the inner balloon 40 is inflatable between a deflated configuration and an inflated configuration.
- the inflation lumen 30 defined by the tubular member 41 of the catheter shaft 22 is in fluid communication with the inner balloon 40 .
- the inflation of the inner balloon 40 can be accomplished by any suitable means known in the art, e.g., by introducing an inflation fluid (e.g., air, saline, etc.) through the inflation lumen 30 into the inner balloon 40 .
- an inflation fluid e.g., air, saline, etc.
- the inner balloon 40 includes a generally cylindrical and straight body portion 112 which extends along a longitudinal axis of the inner balloon 40 .
- a proximal end portion 114 adjacent a proximal neck portion 118 .
- a distal end portion 116 adjacent a distal neck portion 120 .
- the proximal end portion 114 and distal end portion 116 are illustrated as conical; however, the proximal and distal end portions 114 and 116 will typically be slightly rounded since they form part of the inflatable structure of the inner balloon 40 .
- the proximal end 47 of the proximal neck portion 118 connects with the catheter shaft 22 and the distal end 49 of the distal neck portion 120 connects with the tubular member 43 which are typically configured in a fluid tight manner.
- the portions 112 - 120 of the inner balloon 40 are typically formed from a common raw tubing which is inflated under heating so as to stretch into the shape shown in FIG. 4 .
- these portions 112 - 120 of the inner balloon 40 can be formed from the same material, although they may have different wall thicknesses as a result of the different extents to which the raw tubing is inflated, that is stretched during formation of the balloon.
- the body portion 112 will have a thinner balloon wall, whereas the proximal end portion 114 and the distal end portion 116 will have a wall thickness which increases in the direction of reduction of their taper.
- the proximal neck portion 118 and the distal neck portion 120 will have the thickest walls.
- the inner balloon 40 also includes a plurality of ridges 124 which extend from the distal neck portion 120 to the proximal neck portion 118 .
- ridges 124 extend substantially linearly along the axis of the balloon and are substantially equally spaced around the circumference of the inner balloon 40 .
- the ridges are placed on an interior surface of the outer balloon as described in more detail below (see FIG. 9 ).
- the ridges 124 may also be positioned on both of an outside surface of the inner balloon 40 and an interior surface 63 of the outer balloon 42 and can be arranged in an alternating or some other pattern.
- Each ridge 124 has a ridge body portion 126 which extends along the body portion 112 of the inner balloon 40 .
- the ridge body portion 126 of each ridge 124 has a substantially constant height for the length of the body portion 112 , although in other embodiments this height could vary.
- Each ridge 124 includes a proximal tapering section 128 which extends from the ridge body portion 126 along the proximal end portion 114 and a distal tapering section 130 which extends from the ridge body portion 126 along the distal end portion 116 .
- Each ridge 124 includes a proximal outer region 132 adjacent the proximal tapering section 128 and a distal outer region 134 adjacent the distal tapering section 130 wherein the proximal and the distal outer regions 132 , 134 extend over the proximal and the distal neck portions 118 , 120 , respectively.
- Alternative embodiments can include alternative configurations for the proximal and the distal outer regions 132 , 134 such that the proximal and the distal outer regions 132 , 134 are not visible or may have been removed, for instance by being pressed or molded into the proximal and the distal neck portions 118 , 120 or by being cut away, as described below.
- proximal and the distal tapering sections 128 , 130 of each ridge 124 taper from a height that is consistent across or along the ridge body portion 126 to a lower height along the direction of taper of the proximal and the distal neck portions 118 , 120 .
- the proximal and the distal tapering sections 128 , 130 of each ridge 124 taper to a zero height. This reduction in height of the ridges 124 as the inner balloon 40 narrows enhances the flexibility of the inner balloon 40 at the proximal and the distal neck portions 118 , 120 and also ensures that there is no abrupt change in the height of the ridges 124 .
- the proximal and the distal tapering sections 128 , 130 of each ridge 124 exhibit a gradual, linear, reduction in height.
- the reduction in height of the proximal and the distal tapering sections 128 , 130 could vary or have a different overall profile.
- the proximal and the distal tapering sections 128 , 130 of each ridge 124 have a constant height and do not taper to a lower height.
- the ridges 140 extend from a central uniform section 142 along the body portion 112 to a tapering section 144 which gradually tapers all the way down the distal end portion 116 to the distal neck portion 120 .
- Each of the ridges 140 includes a point of contact 146 of the ridges 140 which lies along the distal neck portion 120 which does not have a height relative to an outer surface of the distal neck portion 120 .
- the point of contact 146 is substantially flat with an outer surface of the distal neck portion 120 .
- FIG. 6 shows another embodiment of a ridge 150 on an inner balloon 151 wherein the ridge 150 includes a tapering section 154 , which extends from a central section 152 along the distal end portion 116 and tapers or is reduced in height to a point of contact 156 .
- the point of contact 156 has no height and is substantially flat or flush with an outer surface of the distal neck portion 120 .
- the point of contact 156 is located about mid-way along the distal end portion 116 .
- the tapering sections 130 , 144 , and 154 can have tapers which are other than linear such as rounded, stepped, curved, parabolic, or other geometrical shapes.
- the ridges 124 , 140 , 150 may be slightly rounded or curved at the junction between the body portion 112 and the proximal and the distal end portions 114 , 116 , caused by rounding of the inner balloon 40 during inflation.
- FIGS. 7 and 8 show an embodiment of raw tubing 160 used for the manufacture of the inner balloons 40 described in this application.
- the raw tubing 160 is advantageously a continuous length of tubing having a substantially circular cylindrical tube portion 162 from which extend radially outwardly a plurality of ribs 164 .
- the raw tubing 160 has three ribs 164 extending linearly along the outside of the tube 162 , although the number will correspond to the number of ridges desired.
- the arrangement of the ribs 164 will also be dependent upon the desired shape of the ridges of the inner balloon 40 . For instance, for ridges which extend at least partially helically around the inner balloon 40 , the ribs 164 would also be at least partially helical.
- the ribs 164 are formed to have a generally triangular or otherwise converging shape in axial cross-section, as apparent from FIGS. 7 and 8 , and are preferably made of the same material as the tube 162 .
- the ribs 164 and tube 162 are extruded together, such that they are a single integral component piece with no distinction in terms of material. It is not excluded, however, that the ribs 164 could be made from a different material than that of the tube 162 , for instance a material which is less flexible.
- the raw tubing 160 is inflated in a suitable mold under heat so as to stretch the central part of the raw tubing 160 to form the body portion 112 and the proximal and the distal end portions 114 , 116 of the inner balloon 40 , while the proximal and the distal end portions 114 , 116 of the raw tubing 160 are held radially compressed so as not to inflate and to form the proximal and the distal neck portions 118 , 120 .
- the ribs 164 are kept substantially intact during inflation of the raw tubing 160 .
- a central part of the mold which receives body portion 112 includes a plurality of grooves that are sized to receive the ribs 164 wherein one of the grooves receives one of the ribs 164 therein to preserve the shape of the ribs 164 during inflation of the raw tubing 160 .
- the portions of the ribs 164 which extend along the proximal and the distal neck portions 118 , 120 of the just formed inner balloon 40 are then reduced in height, preferably by laser cutting or otherwise by ablation, grinding or other suitable method.
- the portions of the ribs 164 which overlie the zones of the raw tubing which form the proximal and the distal neck portions 118 , 120 and the proximal and the distal end portions 114 , 116 are squashed during the balloon inflation process.
- the conical portions of the mold which form the proximal and the distal tapering sections 128 , 130 have no or reduced grooves to accommodate the ribs 164 of the raw tubing 160 , as a result of which during the heating and inflation stages the ribs 164 are softened and heat squashed into the wall of the inner balloon 40 .
- Laser cutting can also be used to cut the ribs 164 as it minimizes damage to the inner balloon or ridge material and is accurate.
- the body portions 126 , 142 , 152 of the ridges may be a non-uniform or variable height or a constant non-changing height.
- the body portions 126 , 142 , 152 may have non-uniform heights, may bulge outwardly towards their middle, may reduce in height towards their middle, and may have a plurality of notches along their length.
- the inner balloon 40 is mounted on and bonded or otherwise attached to the distal end of the catheter shaft 22 .
- the inner balloon 40 is pleated and folded.
- the outer balloon 42 illustrated in FIG. 3 the outer balloon 42 is mounted on the distal end of the catheter shaft 22 .
- the outer balloon 42 is mounted around at least a portion of the inner balloon 40 , but preferably mounted entirely around the inner balloon 40 , with the outer balloon 42 enclosing the inner balloon 40 .
- the outer balloon 42 is then pleated and folded.
- the outer balloon 42 includes a working length or a middle portion 70 between a proximal end 72 and a distal end 74 .
- the outer balloon 42 is moveable between a compressed configuration and an expanded configuration.
- the geometry, material and configuration of the outer balloon 42 are selected to withstand an internal pressure of a therapeutic agent and the inflation of the inner balloon 40 without any rupture.
- an inflated outer diameter 56 of the inner balloon 40 spans along the length of the ridge body portion 126 wherein the outer diameter 56 corresponds to an outer edge of ridge 124 that also engages or contacts the interior surface 63 of the outer balloon 42 .
- a flow channel 168 (illustrated in FIG. 2C ) is created by the contact of two adjacent ridges 124 with the interior surface 63 of the outer balloon 42 .
- the flow channel 168 runs the length of the ridge body portion 126 and the body portion 50 wherein the inner balloon 40 and the outer balloon 42 maintain contact with one another.
- the flow channel 168 extends from the ridge body portion 126 to the tapering sections 128 , 130 and from the body portion 50 to the proximal end portion 114 and the distal end portion 116 .
- the flow channel 168 may have a shorter or longer length depending whether the portions of the inner balloon 40 and the outer balloon 42 that are in contact with one another are shorter or longer than illustrated.
- the maximum outer diameter 56 of the inner balloon 40 is smaller than the maximum cross-sectional area or outer diameter 80 of the outer balloon 42 in the expanded configuration.
- the maximum expanded outer diameter 80 of the outer balloon 42 is preferably at the middle portion 70 of the outer balloon 42 , the cross-sectional area being large enough to dilate a portion of the body vessel when in the expanded configuration.
- the flow channel 168 significantly reduces the required pressure to infuse liquid and/or other therapeutic drugs through the outer balloon 42 , thereby reducing the physical stress on the cells in cell therapy and other forms of medical treatment.
- the required infusion pressure used to create a flow path between the pressurized inner balloon and the perforated outer balloon will be more or less identical to the inflation pressure of the inner balloon.
- the infusion pressure has to be below 1 ATM
- the inflation pressure of the inner balloon also need to be below same pressure.
- the flow channel 168 allows a higher inflation pressure of the inner balloon 40 to a range of about 2-8 ATM, depending on the number of ridges, without increasing the infusion pressure.
- the outer balloon 42 is preferably shaped and configured for the intended use in a body vessel.
- the expanded outer diameter 80 of the outer balloon 42 can be about 1.5 mm to about 8 mm, yet when configured for coronary vascular applications, the expanded outer diameter 80 can have a range from about 1.5 mm to about 4 mm.
- the expanded outer diameter 80 of the outer balloon 42 can be about 5-15 mm with a length of approximately 15-60 mm.
- the annular balloon fluid delivery lumen 44 is defined as the space between the inner balloon 40 and the outer balloon 42 .
- the working region of the annular balloon fluid delivery lumen 44 is the space between the body portion 50 of the inner balloon 40 and the middle portion 70 of the outer balloon 42 and the space between the proximal and the distal end portions 114 and 116 of the inner balloon 40 and the outer balloon 42 .
- the annular balloon fluid delivery lumen 44 is in fluid communication with the fluid delivery lumen 33 , shown within a tubular member 35 of the catheter shaft 22 .
- the annular balloon fluid delivery lumen 44 has a constant cross-sectional area along a first portion 90 and a second portion 92 of the longitudinal axis 24 moving distally.
- the second portion 92 of the annular balloon fluid delivery lumen 44 is similar to the cross-sectional area along the first portion 90 .
- the second portion 92 of the annular balloon fluid delivery lumen 44 may have an increasingly larger cross-sectional area along the longitudinal axis 24 moving in the distal direction.
- the change in cross-sectional area of the second portion 92 of the annular balloon fluid delivery lumen 44 can be inversely proportional to the tapering rate of the distal end portion 116 of the inner balloon 40 .
- the holes 46 for releasing fluid from the fluid delivery lumen 33 of the catheter shaft 22 can be disposed around the middle portion 70 of the outer balloon 42 .
- the plurality of holes 46 can have any suitable size and shape suitable to provide a desired rate of fluid release from the annular balloon fluid delivery lumen 44 .
- the plurality of holes 46 has a uniform dimension of about 10 micrometer (0.0004 inch) to about 1 mm (0.04 inch).
- the holes can be formed by any suitable method including mechanical punching, laser cutting, and the like.
- the inner balloon 40 and the outer balloon 42 can be formed and/or molded from a semi-compliant expandable, biocompatible material.
- the inner balloon 40 and the outer balloon 42 are formed from the materials having a similar Young's modulus and expandability for better maintaining the space between the balloons during the entire inflation period.
- the balloons 40 , 42 can be formed from a polyamide (e.g., nylon 12 ) material, a polyamide block copolymer (e.g., PEBA) and blends thereof (e.g., nylon 12 /PEBA and PEBA/PEBA blends).
- Alternative materials include polyolefins, polyolefin copolymers and blends thereof; polyesters (e.g., poly(ethylene terephthalate), PET); polyurethane copolymers with MDI, HMDI or TDI hard segment and aliphatic polyester, polyether or polycarbonate soft segment (e.g., Pellethane, Estane or Bionate); and polyester copolymers with 4GT (PBT) hard segment and aliphatic polyester or polyether soft segments (e.g., Hytrel, Pelprene or Arnitel).
- the balloons 40 , 42 can comprise any suitably non-elastic material such as ionomers, copolyesters, rubbers, or any medical grade polymers suitable for use in forming catheter balloons.
- a proximal seal 82 and a distal seal 84 of the inner balloon 40 and a proximal seal 86 and a distal seal 88 of the outer balloon 42 can be formed in any suitable manner.
- the proximal and distal inner surfaces of the balloons 40 , 42 are sealably attached to the catheter shaft 22 and/or tubular members to prevent any leakage of any fluid.
- Means of sealing the balloons 40 , 42 include, for example, heat sealing, using an adhesive to form the seal, forced convection heating, radio frequency heating, ultrasonic welding, and laser bonding.
- Shrink tubing can be used as a manufacturing aid to compress and fuse each balloon 40 , 42 to the catheter shaft 22 or the tubular member defining the wire guide lumen 38 , the inflation lumen 30 , and/or the fluid delivery lumen 33 .
- the shrink tubing can be removed and disposed of after each balloon 40 , 42 is sealed or can remain on as part of the connected structure. If the catheter shaft 22 has an outer coating, each balloon 40 , 42 can be bonded to the coating or directly to the catheter shaft 22 .
- the therapeutic agent can be delivered through the fluid delivery lumen 33 and through the annular balloon fluid delivery lumen 44 at a pressure effective to deliver the therapeutic agent to the wall of the body vessel through the holes 46 in the outer balloon 42 .
- the therapeutic agent can be delivered by direct local administration to the vessel site or injury through the holes 46 in the outer balloon 42 .
- the antisense compound can have: (i) morpholino subunits linked together by phosphorodiamidate linkages, 2 atoms long, joining the morpholino nitrogen of one subunit to the 5′ exocyclic carbon of an adjacent subunit; and (ii) a sequence of bases attached to the subunits and containing a therapeutically beneficial antisense nucleotide sequence.
- the compound need not necessarily be 100% complementary to the target sequence, it is preferably effective to stably and specifically bind to the target sequence such that expression of the target sequence is modulated.
- the appropriate length of the oligomer to allow stable, effective binding combined with good specificity is about 8 to 42 nucleotide base units, and preferably about 12-25 base units. Mismatches, if present, are less destabilizing toward the end regions of the hybrid duplex than in the middle. Oligomer bases that allow degenerate base pairing with target bases are also contemplated, assuming base-pair specificity with the target is maintained.
- the compound preferably contains internal 3-base triplet complementary to the AUG site, and bases complementary to one or more bases 5′ and 3′ to the start site.
- One preferred compound sequence is the 20 mer having the base sequence: 5′-ACG TTG AGG GGC ATC GTC GC-3′, where the CAT triplet in the sequences binds to the AUG start site, the 6 bases 3 ′ to the CAT sequence extend in the upstream ( 5 ′) direction on the target, and the 11 bases 5 ′ to the CAT sequence extend downstream on the target.
- This compound has enhanced solubility by virtue of having no self-annealing regions.
- the therapeutic agent is a morpholino antisense compound having (i) from 8 to 42 nucleotides, including a targeting base sequence that is complementary to a region that spans the translational start codon of a c-myc mRNA; and (ii) uncharged, phosphorous-containing intersubunit linkages, in an amount effective to reduce the risk or severity of restenosis in the patient.
- a morpholino antisense compound having (i) from 8 to 42 nucleotides, including a targeting base sequence that is complementary to a region that spans the translational start codon of a c-myc mRNA; and (ii) uncharged, phosphorous-containing intersubunit linkages, in an amount effective to reduce the risk or severity of restenosis in the patient.
- the multiple balloon assembly 20 of the multiple balloon catheter 10 can be implanted within a body vessel by conventional medical procedures, such as the Seldinger technique, and subsequently translated through the body vessel over the wire guide 36 through the wire guide lumen 38 to position the distal region at a point of treatment therein.
- the inner balloon 40 can be inflated to a desired diameter by injecting a suitable inflation fluid, such as a pressurized air, gas, or liquid, through the inflation port in the manifold.
- a suitable inflation fluid such as a pressurized air, gas, or liquid
- the inner balloon 40 can be inflated to expand a stenosis in a body vessel such as a coronary artery.
- a fluid containing a therapeutic agent and/or a diagnostic agent (e.g., x-ray contrast media) or any other fluid known to be used in a body vessel can be injected through the injection port, transported within the fluid delivery lumen 33 included in the catheter shaft 22 and introduced to the annular balloon fluid delivery lumen 44 between the outer balloon 42 and the inner balloon 40 .
- the therapeutic agent fluid can be pressurized to deliver the therapeutic agent to the wall of the body vessel through the plurality of holes 46 in the inner balloon 40 before, during, or after inflation of the inner balloon 40 .
- the multiple balloon assembly 20 of the multiple balloon catheter 10 can include radiopaque material to provide a means for locating the multiple balloon catheter 10 within a body vessel.
- the catheter shaft 22 can include one or more marker bands annularly disposed around the outside of the catheter shaft 22 within the inner balloon 40 to define the weeping region of the multiple balloon catheter 10 , or where the fluid is desirable to release to the body vessel.
- radiopaque bands can be added to the catheter shaft 22 .
- Radiopaque marker bands can be used by a clinician to fluoroscopically view and locate the distal portion of the multiple balloon catheter 10 at a point of treatment within a body vessel.
- Various configurations of radiopaque marker bands can be used.
- the radiopaque marker band can be located on a distal end and/or on the catheter shaft 22 within the inner balloon 40 .
- the radiopaque marker bands can be stripes.
- Such radiopaque markers can be constructed by encapsulating a radiopaque material, such as a metallic ring, within the material of catheter shaft 22 .
- a portion of the catheter shaft 22 can be made radiopaque for example by constructing the portion from a radiopaque polymer.
- a polymer can be mixed with a radiopaque filler such as barium sulfate, bismuth trioxide, bismuth subcarbonate, or tungsten.
- the radiopaque material can comprise any suitable opacifying agent, further including bismuth, tantalum, or other suitable agents known in the art.
- the concentration of the agent in the coating can be selected to be adequately visible under fluoroscopy.
- the methods include the step of inserting into a body vessel a multiple balloon catheter.
- the multiple balloon catheter can include: (i) a catheter shaft extending from a proximal end to a distal end and defining an inflation lumen adjacently spaced from a fluid delivery lumen and a wire guide lumen; (ii) a deflated first balloon mounted on the distal end of the catheter shaft in communication with the inflation lumen, the first balloon having a constant cross-sectional area along a middle region between a first end and a second end; and (iii) a deflated second balloon mounted around at least a portion of the first balloon on the distal end of the catheter shaft in communication with the fluid delivery lumen, the second balloon having a middle portion including a plurality of holes in communication with the fluid delivery lumen for releasing a therapeutic agent from the fluid delivery lumen, where
- the multiple balloon catheter can be translated through the body vessel over a wire guide slidably extending through the wire guide lumen to a point of treatment.
- the first balloon can be inflated at the point of treatment to place the second balloon in contact with the wall of the body vessel.
- FIG. 9 Illustrated in FIG. 9 is a multiple balloon catheter 210 that includes a multiple balloon assembly 220 having an outer balloon 242 radially disposed around an inner balloon 240 .
- Multiple balloon assembly 220 is similar to multiple balloon assembly 20 ; therefore, for the sake of brevity similar features will not be described.
- the outer balloon 242 includes a plurality of ridges 224 which extend along a middle portion 250 of the inner balloon 240 . In the illustrated embodiment, there are three ridges 224 , although there could be one, two, or more than three in other embodiments.
- the ridges 224 extend substantially linearly along the axis of the balloon and are substantially equally spaced around the inner circumference of the outer balloon 242 .
- the ridges 224 are placed on an interior surface 263 of the outer balloon 242 and extend to contact an outer surface 251 of an inner balloon 240 to create an inflation lumen 230 .
- the inner balloon 240 defines the inflation lumen 230 extending radially around the tubular member 243 that defines the wire guide lumen 238 .
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Manufacturing & Machinery (AREA)
- Media Introduction/Drainage Providing Device (AREA)
Abstract
Description
Claims (19)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15/336,017 US10300253B2 (en) | 2015-11-10 | 2016-10-27 | Weeping balloon with flow channels for reduced infusion pressure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562253241P | 2015-11-10 | 2015-11-10 | |
US15/336,017 US10300253B2 (en) | 2015-11-10 | 2016-10-27 | Weeping balloon with flow channels for reduced infusion pressure |
Publications (2)
Publication Number | Publication Date |
---|---|
US20170128703A1 US20170128703A1 (en) | 2017-05-11 |
US10300253B2 true US10300253B2 (en) | 2019-05-28 |
Family
ID=57256462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/336,017 Active 2036-12-15 US10300253B2 (en) | 2015-11-10 | 2016-10-27 | Weeping balloon with flow channels for reduced infusion pressure |
Country Status (3)
Country | Link |
---|---|
US (1) | US10300253B2 (en) |
EP (1) | EP3374016A1 (en) |
WO (1) | WO2017083112A1 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11040178B2 (en) | 2014-11-03 | 2021-06-22 | Cagent Vascular, Llc | Serration balloon |
US11141573B2 (en) | 2008-03-21 | 2021-10-12 | Cagent Vascular, Inc. | Method for plaque serration |
US11166742B2 (en) | 2008-03-21 | 2021-11-09 | Cagent Vascular, Inc. | Method of enhancing drug uptake from a drug-eluting balloon |
US11219750B2 (en) | 2008-03-21 | 2022-01-11 | Cagent Vascular, Inc. | System and method for plaque serration |
US11266818B2 (en) | 2015-09-17 | 2022-03-08 | Cagent Vascular, Inc. | Wedge dissectors for a medical balloon |
US11369779B2 (en) | 2018-07-25 | 2022-06-28 | Cagent Vascular, Inc. | Medical balloon catheters with enhanced pushability |
US11738181B2 (en) | 2014-06-04 | 2023-08-29 | Cagent Vascular, Inc. | Cage for medical balloon |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6804370B2 (en) * | 2017-03-31 | 2020-12-23 | テルモ株式会社 | Medical long body |
WO2021097137A1 (en) * | 2019-11-12 | 2021-05-20 | Microvention, Inc. | Balloon catheter with enhanced characteristics |
US20220080155A1 (en) * | 2020-09-11 | 2022-03-17 | Oscor Inc. | Guiding sheath with pressure relief channel |
Citations (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4437856A (en) | 1981-02-09 | 1984-03-20 | Alberto Valli | Peritoneal catheter device for dialysis |
US5236659A (en) | 1988-10-04 | 1993-08-17 | Cordis Corporation | Tailoring expansion properties of balloons for medical devices |
US5336178A (en) | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5792105A (en) | 1996-09-11 | 1998-08-11 | Boston Scientific Corporation | Multichannel balloon catheter for delivering fluid |
US7094765B1 (en) | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
WO2009036135A1 (en) | 2007-09-12 | 2009-03-19 | Cook Incorporated | Balloon catheter for delivering a therapeutic agent |
US20090254064A1 (en) | 2008-04-08 | 2009-10-08 | Cook Incorporated | Weeping balloon catheter |
US20110160756A1 (en) | 2009-12-29 | 2011-06-30 | William Cook Europe Aps | Cutting or Scoring Balloon, System and Method of Making a Cutting or Scoring Balloon |
US8162880B2 (en) | 2008-01-18 | 2012-04-24 | Swaminathan Jayaraman | Delivery of therapeutic and marking substance through intra lumen expansion of a delivery device |
US20120130407A1 (en) | 2010-11-22 | 2012-05-24 | Cook Medical Technologies Llc | Scoring balloon and method of making same |
US8348890B2 (en) | 2011-03-01 | 2013-01-08 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
US8454637B2 (en) | 2011-01-20 | 2013-06-04 | Cook Medical Technologies Llc | Scoring balloon with offset scoring elements |
US20140088624A1 (en) | 2012-09-24 | 2014-03-27 | Cook Medical Technologies Llc | Cutting or scoring balloon and apparatus therefor |
US20140155927A1 (en) | 2011-12-02 | 2014-06-05 | Cook Medical Technologies Llc | Integral dilation element for a balloon catheter |
-
2016
- 2016-10-27 WO PCT/US2016/059103 patent/WO2017083112A1/en active Application Filing
- 2016-10-27 EP EP16794156.6A patent/EP3374016A1/en not_active Withdrawn
- 2016-10-27 US US15/336,017 patent/US10300253B2/en active Active
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4437856A (en) | 1981-02-09 | 1984-03-20 | Alberto Valli | Peritoneal catheter device for dialysis |
US5236659A (en) | 1988-10-04 | 1993-08-17 | Cordis Corporation | Tailoring expansion properties of balloons for medical devices |
US5336178A (en) | 1992-11-02 | 1994-08-09 | Localmed, Inc. | Intravascular catheter with infusion array |
US5792105A (en) | 1996-09-11 | 1998-08-11 | Boston Scientific Corporation | Multichannel balloon catheter for delivering fluid |
US7094765B1 (en) | 1999-01-29 | 2006-08-22 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
US20060269587A1 (en) | 1999-01-29 | 2006-11-30 | Avi Biopharma, Inc. | Antisense restenosis composition and method |
WO2009036135A1 (en) | 2007-09-12 | 2009-03-19 | Cook Incorporated | Balloon catheter for delivering a therapeutic agent |
US8162880B2 (en) | 2008-01-18 | 2012-04-24 | Swaminathan Jayaraman | Delivery of therapeutic and marking substance through intra lumen expansion of a delivery device |
US8591461B2 (en) * | 2008-04-08 | 2013-11-26 | Cook Medical Technologies Llc | Weeping balloon catheter |
US20090254064A1 (en) | 2008-04-08 | 2009-10-08 | Cook Incorporated | Weeping balloon catheter |
US8034022B2 (en) | 2008-04-08 | 2011-10-11 | Cook Medical Technologies Llc | Weeping balloon catheter |
US20110160756A1 (en) | 2009-12-29 | 2011-06-30 | William Cook Europe Aps | Cutting or Scoring Balloon, System and Method of Making a Cutting or Scoring Balloon |
US20120130407A1 (en) | 2010-11-22 | 2012-05-24 | Cook Medical Technologies Llc | Scoring balloon and method of making same |
US8454637B2 (en) | 2011-01-20 | 2013-06-04 | Cook Medical Technologies Llc | Scoring balloon with offset scoring elements |
US8348890B2 (en) | 2011-03-01 | 2013-01-08 | Sanovas, Inc. | Nested balloon catheter for localized drug delivery |
US20140155927A1 (en) | 2011-12-02 | 2014-06-05 | Cook Medical Technologies Llc | Integral dilation element for a balloon catheter |
US20140088624A1 (en) | 2012-09-24 | 2014-03-27 | Cook Medical Technologies Llc | Cutting or scoring balloon and apparatus therefor |
Non-Patent Citations (2)
Title |
---|
International PatentApplication PCT/US2016/059103 Partial Search Report dated Jan. 25, 2017. 8 pages. |
International PatentApplication PCT/US2016/059103 Search Report and Written Opinion dated Mar. 20, 2017. 19 pages. |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11529501B2 (en) | 2008-03-21 | 2022-12-20 | Gagent Vascular, Inc. | System and method for plaque serration |
US11141573B2 (en) | 2008-03-21 | 2021-10-12 | Cagent Vascular, Inc. | Method for plaque serration |
US11166742B2 (en) | 2008-03-21 | 2021-11-09 | Cagent Vascular, Inc. | Method of enhancing drug uptake from a drug-eluting balloon |
US11219750B2 (en) | 2008-03-21 | 2022-01-11 | Cagent Vascular, Inc. | System and method for plaque serration |
US11229777B2 (en) | 2008-03-21 | 2022-01-25 | Cagent Vascular, Inc. | System and method for plaque serration |
US11738181B2 (en) | 2014-06-04 | 2023-08-29 | Cagent Vascular, Inc. | Cage for medical balloon |
US11040178B2 (en) | 2014-11-03 | 2021-06-22 | Cagent Vascular, Llc | Serration balloon |
US11298513B2 (en) | 2014-11-03 | 2022-04-12 | Cagent Vascular, Inc. | Serration balloon |
US11701502B2 (en) | 2014-11-03 | 2023-07-18 | Cagent Vascular, Inc. | Serration balloon |
US11266819B2 (en) | 2015-09-17 | 2022-03-08 | Cagent Vascular, Inc. | Wedge dissectors for a medical balloon |
US11491314B2 (en) | 2015-09-17 | 2022-11-08 | Cagent Vascular Lac. | Wedge dissectors for a medical balloon |
US11717654B2 (en) | 2015-09-17 | 2023-08-08 | Cagent Vascular, Inc. | Wedge dissectors for a medical balloon |
US11266818B2 (en) | 2015-09-17 | 2022-03-08 | Cagent Vascular, Inc. | Wedge dissectors for a medical balloon |
US11369779B2 (en) | 2018-07-25 | 2022-06-28 | Cagent Vascular, Inc. | Medical balloon catheters with enhanced pushability |
Also Published As
Publication number | Publication date |
---|---|
US20170128703A1 (en) | 2017-05-11 |
WO2017083112A1 (en) | 2017-05-18 |
EP3374016A1 (en) | 2018-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10300253B2 (en) | Weeping balloon with flow channels for reduced infusion pressure | |
US9174030B2 (en) | Weeping balloon catheter | |
EP2195068B1 (en) | Balloon catheter for delivering a therapeutic agent | |
US8740843B2 (en) | Coated balloon catheter | |
KR101598546B1 (en) | Balloon catheter having multiple inflation lumens and related methods | |
EP1549377B1 (en) | Extruded tubing with discontinuous striping | |
US20110137245A1 (en) | Balloon catheter with embedded rod | |
US9028443B2 (en) | Weeping balloon catheter with drug delivery balloon in fluid communication with combination lumen | |
CN104056338A (en) | Catheter For Uniform Delivery Of Medication | |
CN109414571A (en) | A kind of medicament elution sacculus | |
CN115154854B (en) | Double-layer medicine carrying balloon catheter | |
CN118178841A (en) | Device for realizing drug delivery by utilizing balloon, drug delivery device and minimally invasive medical system | |
US10632291B2 (en) | Medical elongated body | |
US10918842B2 (en) | Balloon catheter | |
GB2502956A (en) | A catheter having balloons located around the circumference of the catheter | |
JP2013070882A (en) | Balloon catheter | |
JP7381201B2 (en) | drug administration catheter | |
JP2024141505A (en) | Balloon catheter | |
MX2008007971A (en) | Balloon catheter with centralized vent hole |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: COOK MEDICAL TECHNOLOGIES LLC, INDIANA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WILLIAM COOK EUROPE APS;REEL/FRAME:040159/0428 Effective date: 20151116 Owner name: WILLIAM COOK EUROPE APS, DENMARK Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PEDERSEN, PER ELGAARD;REEL/FRAME:040159/0340 Effective date: 20151103 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
AS | Assignment |
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT, DELAWARE Free format text: SECURITY INTEREST;ASSIGNOR:COOK MEDICAL TECHNOLOGIES LLC;REEL/FRAME:066700/0277 Effective date: 20240227 |